Urinary Tumor DNA–based Liquid Biopsy in Bladder Cancer Management: A Systematic Review
European Urology Focus · 2025-11 · 11 (6) · 978-990
DOI: 10.1016/j.euf.2025.06.009 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Urology Focus, 2025-11. Verfasst von Joanne Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School, Providence, RI, USA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Urinary tumor DNA (utDNA) has emerged as a promising biomarker in the care, diagnosis, early detection, recurrence monitoring, and prognosis of bladder cancer (BCa). Its noninvasive nature, ease of access, and cost effectiveness make it an attractive option for both patients and health care providers. This review describes the current state of utDNA as a marker of BCa. METHODS: Articles published between 2015 and 2025 on current utDNA-based techniques in BCa were identified and analyzed for relevance and insight into utDNA research and usage. KEY FINDINGS AND LIMITATIONS: Recent investigations underscore the noninvasiveness and superior tumor detection capabilities of utDNA, particularly in the detection of minimal residual disease. Moreover, utDNA provides actionable information, such as tumor grade and staging information, to support precise treatment decisions, including targeted immunotherapy regimens and bladder preservation strategies. Although utDNA has shown promising results in small studies, larger studies must be performed before it can be considered as a standard procedure in clinical practice. CONCLUSIONS AND CLINICAL IMPLICATIONS: Urinary tumor DNA has demonstrated great potential to improve on most, if not all, stages of detection, treatment, and monitoring of BCa. By preserving the low cost and noninvasiveness of urine cytology, and by replacing its suboptimal accuracy with a precision rivaling and often exceeding cystoscopy and circulating tumor DNA-based methods, utDNA offers patients a more comfortable, repeatable, and accurate way of detecting BCa. With increased sensitivity and accuracy, everything from low-grade tumors to the earliest signs of recurrence can be detected more effectively, optimizing patient treatment courses and improving outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School, Providence, RI, USA.
- Department of Pathology and Laboratory Medicine, New York University Grossman School of Medicine and NYU Langone Health, New York, NY, USA.
- Department of Surgery, Cordoba University Medical School, Cordoba, Spain.
- Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
- Institute of Pathological Anatomy, Department of Medicine, University of Udine, Udine, Italy.
- Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Zitieren
APA
Lee, J., Chen, F., Lopez-Beltran, A., Necchi, A., Cimadamore, A., Spiess, P. E., Li, R., Roy-Chowdhuri, S., Montironi, R., Golijanin, D., Luchini, C., & Cheng, L. (2025). Urinary Tumor DNA–based Liquid Biopsy in Bladder Cancer Management: A Systematic Review. European Urology Focus, 11(6), 978-990. https://doi.org/10.1016/j.euf.2025.06.009
Vancouver
Lee J, Chen F, Lopez-Beltran A, Necchi A, Cimadamore A, Spiess PE, et al. Urinary Tumor DNA–based Liquid Biopsy in Bladder Cancer Management: A Systematic Review. European Urology Focus. 2025;11(6):978-990. doi:10.1016/j.euf.2025.06.009
BibTeX
@article{Lee2025,
author = {Lee, Joanne and Chen, Fei and Lopez-Beltran, Antonio and Necchi, Andrea and Cimadamore, Alessia and Spiess, Philippe E and Li, Roger and Roy-Chowdhuri, Sinchita and Montironi, Rodolfo and Golijanin, Dragan and Luchini, Claudio and Cheng, Liang},
title = {Urinary Tumor DNA–based Liquid Biopsy in Bladder Cancer Management: A Systematic Review},
journal = {European Urology Focus},
year = {2025},
volume = {11},
number = {6},
pages = {978--990},
doi = {10.1016/j.euf.2025.06.009}
}
EUVIMED